Galapagos NV
GLPG
#5033
Rank
NZ$3.31 B
Marketcap
NZ$49.30
Share price
0.00%
Change (1 day)
-14.52%
Change (1 year)

Earnings for Galapagos NV (GLPG)

Earnings in 2026 (TTM): NZ$0.96 Billion

According to Galapagos NV's latest financial reports the company's current earnings are NZ$1.22 Billion. In 2025 the company made an earning of NZ$0.65 Billion, an increase over its 2024 earnings that were of -NZ$10.28 Million. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Galapagos NV from 2015 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) NZ$0.96 B47.73%
2025 NZ$0.65 B-6464.81%
2024 -NZ$10.28 Million-82.77%
2023 -NZ$59.64 Million-85.59%
2022 -NZ$0.42 Billion60.71%
2021 -NZ$0.26 Billion-60.08%
2020 -NZ$0.65 Billion-331.44%
2019 NZ$0.27 B-523.76%
2018 -NZ$65.8 Million-72.34%
2017 -NZ$0.24 Billion-329.59%
2016 NZ$0.10 B-144.3%
2015 -NZ$0.24 Billion

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Johnson & Johnson
JNJ
NZ$46.59 B 4,638.20%๐Ÿ‡บ๐Ÿ‡ธ USA
Abbott Laboratories
ABT
NZ$14.46 B 1,371.11%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
NZ$15.46 B 1,472.71%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
NZ$12.73 B 1,194.53%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
NZ$13.67 B 1,290.29%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
NZ$25.48 B 2,491.11%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
NZ$14.02 B 1,326.36%๐Ÿ‡ฌ๐Ÿ‡ง UK
Fortress Biotech
FBIO
NZ$0.25 B-73.63%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
NZ$2.85 B 190.17%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel